

Increased household transmission and immune escape of the SARS-CoV-2 Omicron variant compared to the Delta variant: evidence from Norwegian contact tracing and vaccination data

Neda Jalali¹, Hilde K. Brustad², Arnaldo Frigessi^{2,3}, Emily MacDonald¹, Hinta Meijerink¹, Siri Feruglio¹, Karin Nygård¹, Gunnar Isaksson Rø¹, Elisabeth H. Madslie¹, Birgitte Freiesleben De Blasio^{1,2}

¹ Norwegian Institute of Public Health, Oslo, Norway

² Oslo Centre for Biostatistics and Epidemiology, University of Oslo, Norway

³ Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Norway

Correspondence: Birgitte Freiesleben De Blasio

email: Birgitte.Freiesleben.DeBlasio@fhi.no

Department of Methods Development and Analytics

Division of Infection Control

Norwegian Institute of Public Health/

Keywords: SARS-CoV-2; Omicron; secondary attack rate, household transmission, vaccine effectiveness

Abstract

We compared the secondary attack rate (SAR) of the SARS-CoV-2 Omicron and Delta variants in households using contact tracing data. Omicron SAR was higher (41%) than Delta (35%), likely due to immune evasion. Booster dose reduces risk of infection but has limited effect on preventing Omicron transmission.

INTRODUCTION

By the end of 2021, rapid global spread of the novel SARS-CoV-2 Omicron variant of concern (VoC) (Pangolin designation B.1.1.529 BA.1) caused major concern and urgent need for knowledge about its transmissibility, severity of disease and ability to escape vaccine immunity [1, 2]. In Norway, the first SARS-CoV-2 Omicron case was reported on 30 November at a time when the Delta variant was dominating. At the same time, a large Omicron outbreak was detected after a Christmas party, causing an attack rate of 74% among participants, of which most (98%) were fully vaccinated [3]. Over the next 4-6 weeks, Omicron rapidly took over for the Delta variant in Norway and by week 2 in 2022 the Omicron variant was detected in > 90% of the weekly national samples screened or sequenced for virus variants [4]. Early studies report that Omicron might have higher transmissibility than Delta [5-7], although infection seems to cause less severe disease and lower risk of hospitalization [1, 8]. The Omicron variant's ability to escape vaccine immunity [9-11] is likely an important contributor to the current rapid spread of the disease [7]. A highly immune evasive VoC could potentially challenge global control strategies. Thus, timely and relevant knowledge about transmissibility and risk of infection concerning vaccination status of the population is of particular importance to guide health authorities.

Here, we use contact tracing data collected by Norwegian municipalities to estimate and compare household secondary attack rate (SAR) for the Omicron and Delta variants at a time when both variants were circulating throughout the country.

METHODS

Study design, study population and data sources

We conducted a registry-based cohort study using data from the Norwegian COVID-19 pandemic preparedness register, Beredt C19 [12]. Beredt C19 receives individual-level information from Norwegian health registries which can be linked using unique personal identification numbers. The purpose of the preparedness register is to enable rapid

knowledge generation on the spread of COVID-19 to support national authorities in crisis management and preparedness planning. Beredt C19 collects information from various national registries, including information on Norwegian residents who have tested positive for SARS-CoV-2, date of testing, variant detection, vaccination record, and demographics. Furthermore, the register receives digital contact tracing data on a voluntary basis from Norwegian municipalities, enabling the linkage of index cases to their traced contacts. Detailed information on the specific Beredt C19 data sources that were used in this study is shown in Supplementary S1.

The study population were households registered in the municipal contact tracing system of 64 municipalities during the study period. We defined a primary case as the first person in a household (according to the testing date) to test positive for either the SARS-CoV-2 Omicron or Delta variant during the study period. Virus variant information was based on either PCR variant screening, whole genome sequencing, or both. Household contacts of the primary cases were identified by matching household identification numbers of the primary case and contacts. We limited our study to households of sizes between 2 – 6 individuals to exclude multi-generation households, care facilities and institutions. Furthermore, five primary cases and 24 contacts were excluded from the analysis due to previously reported SARS-CoV-2 infection. We defined a household secondary case as any individual registered as a close contact of the primary case, living in the same household and who tested positive for SARS-CoV-2 ≤ 10 days after the test date of the primary case. Vaccination status of the cases and contacts were separated into the following categories: i) unvaccinated, ii) partially vaccinated, iii) fully vaccinated and iv) booster vaccinated. Further information on definitions used in the study is described in Supplementary S2. We limited data collection to the period from 14 December 2021 to 14 January 2022 to avoid bias due to changes in the national testing, isolation, quarantine, and contact tracing regimes (TISK). There were no differences in the TISK regime for Omicron and Delta during the study period.

Statistical Analysis

We used binomial regression with a log link to estimate the secondary attack rate (SAR) within households, comparing Delta with Omicron, assuming test activity and case finding did not vary by variant [13]. The binomial regression model was stratified for different covariates, including vaccination status, age group, and gender, of the contacts and primary cases to find the relative risk (RR) between them. Vaccine effectiveness (VE) against infection among household contacts was calculated using the following equation: $VE = 1 - (SAR_{\text{vaccinated contacts}} / SAR_{\text{unvaccinated contacts}})$. Contacts aged 0-15 years were excluded from the VE-calculations because children 12-15 years were only eligible for one vaccine dose, and young children 0-11 years were not eligible for vaccination at the time. Significance level (α) was set at 5%. Statistical analyses were performed with Rstudio 1.3.1056.

RESULTS

In total, 979 primary cases with confirmed Delta (46%) or Omicron (54%) and 1888 household contacts representing 51/356 municipalities and 8/11 counties were registered in the contact tracing system and included in the final dataset. Characteristics of the cases and contacts are presented in Supplementary S3.

The main findings are presented in Table 1-A,B,C. The overall SAR of households with Omicron was estimated at 41% (CI₉₅:38-44) compared to 35% (CI₉₅:31-38) with Delta giving a significantly higher risk of infection in households with Omicron relative to Delta (Table 1A). We found no significant difference in SAR between Delta and Omicron households when a child (< 16 years) was the primary case. Likewise, we found no significant difference in SAR between Omicron and Delta in households of unvaccinated primary cases (40% vs 35%) or contacts (47% vs 45%). The risk of infection in fully vaccinated contacts was higher (RR: 1.37; CI₉₅ 1.15-1.64) in households with Omicron relative to Delta. We observed no significant difference in risk of infection among booster vaccinated contacts. Generally, the

SAR in households with booster vaccinated cases and contacts was lower than in households with unvaccinated cases and contacts. Primary cases who were booster vaccinated were found to have a considerably higher risk (RR: 5.75; CI₉₅ 1.32-100) of transmitting SARS-CoV-2 to their household contacts with Omicron compared to Delta. A similar trend was observed when the primary case was fully vaccinated, although the relative risk was lower (RR 1.18; CI₉₅ 1.04-1.46).

VE for booster vaccinated adult contacts was lower for Omicron (47%) compared to Delta (62%) but higher than for fully vaccinated (Table 1B). In the latter group, we found the protection against infection with Omicron to be 16%, whereas 46% for Delta.

When estimating the risk of infection, stratified by age groups, gender and the time since last dose (in fully vaccinated), we found no significant differences (Table 1C).

DISCUSSION

During a period when both the Omicron and Delta were circulating, we found an overall higher household ten days secondary attack rate (SAR) for the Omicron (41%) compared to the Delta (35%) variant. This finding aligns with observations from Denmark [7] and the UK [14]. The SAR estimates were generally higher in our study, which could be due to various reasons such as differences in the testing regimes or discrepancies in the capacity and procedures for registering household contacts; see Supplementary S4 for study limitations. In this study, we have used contact tracing data, and this may give higher estimates of SAR than registry-based studies, since the exposure is identified through personal interviews. Furthermore, since the included children <16 years were mostly unvaccinated or partially vaccinated, this could contribute to the overall higher household SAR for both Delta and Omicron observed in our study. The overall difference in SAR between the strains was surprisingly small, given the rapid takeover of Omicron from Delta in Norway. This finding may be due to the study setting, as household exposure is often prolonged and repeated.

Unfortunately, inclusion of non-household contacts was not possible due to variations in contact tracing practices during the study period and between localities.

Similar to Lyngse et al., we found no significant difference in the SAR in households with Omicron and Delta among unvaccinated or partially vaccinated, suggesting that intrinsic transmissibility is not particularly higher in the Omicron variant compared to Delta. This finding contradicts early assumptions that the Omicron is fundamentally more transmissible than Delta [15].

As expected, vaccination with two and three doses seemed to give lower protection against infection for Omicron than Delta, which is supported by other epidemiological studies and neutralization studies, likely related to the large number of mutations in the spike (S) protein compared to Delta [9]. While the protective effect of booster dose against Omicron infection (VE) was significant, the protection against onwards transmission seems rather low, compared to Delta. Our results indicate that booster vaccinated primary cases had a five-fold higher risk of transmitting Omicron to their household contacts relative to Delta. However, we did not adjust for age and time since vaccination, and thus, our results should be interpreted with caution.

In conclusion, our study indicates that the higher overall SAR among household contacts of Omicron cases is most likely due to lower vaccine effectiveness and not higher intrinsic transmissibility of this variant. As reported by others, booster doses decrease this risk of infection with Delta and Omicron, but our findings suggest that it has limited effect on preventing Omicron transmission.

Notes

Acknowledgements. We are grateful to the Norwegian municipalities and their local contact tracing teams for gathering and sharing of data, and to the Norwegian emergency preparedness registry BERECT-C19 for access to data.

Disclaimer. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Funding. The study was funded by the Norwegian Institute of Public Health (NIPH).

Potential conflicts of interest. The authors report no conflict of interest.

Table 1: Secondary attack rates (SAR) and relative risks (RR) of Omicron versus Delta stratified by contacts' age, primary cases' age, vaccination status of contacts, primary cases, gender, and time since last vaccination in fully vaccinated contacts in Norway, 14 December 2021 to 14 January 2022.

Table	Description	Omicron		Delta	
1-A	SAR, between variant RR	SAR (95% CI)	RR (95% CI)	SAR (95% CI)	RR
	Overall	0.41 (0.38 - 0.44)	1.18 (1.05 - 1.33)	0.35 (0.31 - 0.38)	Ref
	Age of contacts				
	<16 years	0.47 (0.41 - 0.53)	1.17 (0.97 - 1.42)	0.49 (0.34- 0.46)	Ref
	16+ years	0.39 (0.35 - 0.42)	1.21 (1.03 - 1.4)	0.32 (0.28 - 0.36)	Ref
	Age of primary cases				Ref
	<16 years	0.47 (0.41 - 0.53)	1.17 (0.97 - 1.42)	0.49 (0.34- 0.46)	Ref
	16+ years	0.39 (0.35 - 0.42)	1.21 (1.03 - 1.4)	0.32 (0.28 - 0.36)	Ref
	Vacc. status, contacts				
	unvaccinated	0.47 (0.41 - 0.53)	1.03 (0.86 - 1.24)	0.45 (0.39 - 0.51)	Ref
	partial	0.46 (0.36 - 0.56)	1.47 (0.98 - 2.34)	0.31 (0.21 - 0.43)	Ref
	full	0.41 (0.37 - 0.45)	1.37 (1.15-1.64)	0.30 (0.26 - 0.35)	Ref
	boosted	0.26 (0.19 - 0.34)	1.21 (0.73- 2.16)	0.22 (0.13 - 0.33)	Ref
	Vacc. status, primary cases				
	unvaccinated	0.40 (0.34 - 0.46)	1.13 (0.92 - 1.38)	0.35 (0.31 - 0.4)	Ref
	partial	0.39 (0.30 - 0.49)	1.07 (0.72-1.60)	0.37 (0.26 - 0.48)	Ref
	full	0.43 (0.39 - 0.47)	1.23 (1.04-1.46)	0.35 (0.30 - 0.40)	Ref
	boosted	0.27 (0.18-0.38)	5.75 (1.32 - 100)	0.05 (0.003 - 0.19)	Ref
1-B	VE by contact vacc. status (16+)	Omicron VE (%)		Delta VE (%)	
	unvaccinated	Ref		Ref	
	partial	16 (0 - 51)		35 (0 - 77)	
	full	16 (0 - 37)		46 (28 - 58)	
	boosted	47 (17 - 64)		62 (38 - 78)	
1-C	RR within variant	Omicron, RR		Delta, RR	
	Age of contacts				
	<16 years	1.48 (0.96 - 2.57)		1.15 (0.72 - 2.20)	
	16-44 years	1.28 (0.84 - 2.23)		0.88 (0.55 - 1.69)	
	45-64 years	1.17 (0.76 - 2.01)		0.98 (0.6 - 1.9)	
	65+ years	Ref		Ref	
	Gender of contacts (16+)				
	female	Ref		Ref	
	male	0.87 (0.72 - 1.04)		1.07 (0.84 - 1.37)	
	Time since last vacc., (16+)				
	full vacc. contacts				
	≤ 6 months	Ref		Ref	
	>6 months	0.907 (0.566-1.305)		0.685 (0.358-1.135)	

REFERENCES

1. UK Health Security Agency. Sars-cov-2 variants of concern and variants under investigation in England. Technical briefing: Update on hospitalisation and vaccine effectiveness for Omicron VOC-21NOV-01 (B.1.1.529). **2021**.
2. World Health Organization. Enhancing response to Omicron (COVID-19 variant B.1.1.529): Technical brief and priority actions for Member States. **2021**.
3. Brandal LT, MacDonald E, Veneti L, et al. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. *Euro Surveill* **2021**; 26(50): 2101147.
4. Norwegian Institute of Public Health. COVID-19 ukerapport - uke 2. **2022**.
5. Nishiura H, Ito K, Anzai A, Kobayashi T, Piantham C, Rodriguez-Morales AJ. Relative Reproduction Number of SARS-CoV-2 Omicron (B.1.1.529) Compared with Delta Variant in South Africa. *Journal of Clinical Medicine* **2022**; 11(1): 30.
6. Zhang L, Li Q, Liang Z, et al. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron. *Emerging Microbes & Infections* **2022**; 11(1): 1-5.
7. Lyngse FP, Mortensen LH, Denwood MJ, et al. SARS-CoV-2 Omicron VOC Transmission in Danish Households. *medRxiv* **2021**.
8. Veneti L, Bøås H, Bråthen Kristoffersen A, et al. Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022. *Eurosurveillance* **2022**; 27(4): 2200077.
9. Dejnirattisai W, Shaw RH, Supasa P, et al. Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. *The Lancet* **2021**.
10. Hansen CH, Schelde AB, Moustsen-Helms IR, et al. Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study. *medRxiv* **2021**.
11. Hu J, Peng P, Cao X, et al. Increased immune escape of the new SARS-CoV-2 variant of concern Omicron. *Cell Mol Immunol* **2022**.
12. Norwegian Institute of Public Health. Emergency preparedness register for COVID-19 (Beredt C19). Available at: <https://www.fhi.no/en/id/infectious-diseases/coronavirus/emergency-preparedness-register-for-covid-19/>. Accessed January 2022.
13. Shaker Y, Kenah E. Estimating and interpreting secondary attack risk: Binomial considered biased. *PLoS Comput Biol* **2021**; 17(1): e1008601.
14. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England, Technical briefing 31. **2021**.
15. Torjesen I. Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear. *BMJ* **2021**; 375: n2943.